BCRegMed 2019 Asset Map
Why Asset Maps? Asset maps identify the strengths, resources, and limitations within a community. They provide an inventory of the current landscape--of the knowledge and skills, existing partnerships and opportunities, and trends in investments and grants--and help uncover new partners, opportunities, and under-utilized resources. Asset maps serve to determine and bridge gaps between what exists, and what is desired.
What is BCREGMED? The BC Regenerative Medicine Initative is a UBC-funded research excellence cluster established in 2017 by Dr. Fabio Rossi. Launched as a way to unite members of the regenerative medicine community, our goal is to position Regenerative Medicine as an exemplar life science sector that Canada can lead in, and that can prototype government recommendations fo innovative cluster growth (i.e., training, scaling, local procurement, etc.).
BCREGMED cooperates closely with UBC's flagship School of Biomedical Engineering. The SBME is founded through partnerships with more than 20 joint faculty members that are leaders in research areas from molecualr and cellular engineering, to biological imaging, computational biology and human interfacing devices. Much like BCREGMED, the SBME aims to facilitate the translation of scientific discovery to fundamental new biomedical technologies and innovative application to benefit human health.
By participating in this survey, you are not only helping us improve current activities and determine new directions for the program and/or programs that need to be developed, but you are providing material with which we can leverage the government to improve regenerative medicine funding in BC.
Required questions are indicated with an asterisk
If you have any questions, please email firstname.lastname@example.org
Gene-Based Medicine (Gene Therapy) seeks to modify or introduce genes into a patient's body with the goal of durably treating, preventing or potentially even curing disease, including several types of cancer, viral diseases, and inherited disorders.
Genome Editing is a technique by which DNA is inserted, replaced, removed, or modified at locations in the human genome for therapeutic benefit in order to treat cancer, rare inherited disorders, HIV, or other diseases.
Cellular Immunotherapy is the use of engineering (e.g. synthetic biology) approaches to direct immune cells toward a specific target/function
Cell Therapy is the administration of viable, often purified cells into a patient's body to grow, replace, or repair damaged tissue for the treatment of a disease. A variety of different types of cells can be used in cell therapy.
Tissue-Engineered Products & Biomaterials Tissue Engineering seeks to restore, maintain, improve, or replace damaged tissues and organs through the combination of scaffolds, cells, and/or biologically active molecules.
Endogenous regeneration involves the delivery of exogenous biologics or pharmaceuticals modulating the subject's own cells to improve regenerative outcomes
COMMITTED TO DIVERSITY
Why we are asking you to self-identify
Equity, diversity and inclusivity (EDI) strengthens research, and leads to healthy people and healthy communities.
BCRegMed is committed to advancing equity and diversity within our research excellence cluster. We are committed to creating and maintaining an inclusive environment, in which diversity is welcomed and respected. We consider diversity to be foundational to excellence in research, education and engagement.
The questions are primarily based on the current standard used by Statistics Canada in the Census, and wording from the Employment Equity Act. If you have comments or suggestions regarding this data collection, please send queries to:
Program Manager: email@example.com
Self-identification information is collected on a voluntary basis. This information will be stored electronically in our secure database and access is limited to agency staff on a need to know basis. Your self-identification information is not part of your application, and is neither accessible to, nor shared with, external reviewers and/or selection committee members in an identifiable form.
Choosing not to self-identify will have no consequences.
Your data will be used for the purposes of program operations and planning, program performance measurement and monitoring, evaluation and audits, and may be used en masse to report to the University of British Columbia, government, or to the public. Self-identification information will be reported in a de-identified form (e.g., aggregate) to ensure protection of any individual.
By voluntarily submitting your self-identification information, you are confirming that you have read and understood this Privacy Notice Statement and agree to provide your personal information in accordance with it.
Please note that all other information being collected will remain anonymous, and will not be used or disclosed for other purposes. If you have any questions about the collection of your personal information, please contact Lisa Borecky (firstname.lastname@example.org).